Mecanismos inmunitarios en la patogénesis de la urticaria crónica espontánea

  • Jorge Sánchez
  • Claudia Sánchez
  • Mauricio López
  • Margarita María Velásquez-Lopera
Palabras clave: Basófilos, Habones, Histamina, Mastocitos, Patogénesis, Urticaria

Resumen

Introducción: La urticaria crónica espontánea es una enfermedad de la piel, caracterizada por habones y prurito de más de 6 semanas de evolución.
Metodología: En este artículo intentamos realizar una revisión de la evidencia disponible sobre los mecanismos que pueden intervenir en la patogénesis de la urticaria. El conocimiento de estos mecanismos puede permitir un mejor abordaje clínico y el diseño de medicamentos más específicos y efectivos. Revisión narrativa. Términos de búsqueda: abiertos. Bases consultadas: Pubmed, Google scholar, scopes.
Resultados: Los mecanismos que llevan a la patogénesis de la urticaria crónica espontánea parecen ser varios y confluyen en la activación por mecanismos autorreactivos de los mastocitos y los basófilos, lo que induce la liberación de histamina y otros mediadores.
Conclusión: Diferentes vías de activación han sido identificadas en donde participan la IgG, la IgE, la cascada de la coagulación, los factores del complemento, diferentes citocinas, neurotrofinas y neuropéptidos.

Biografía del autor/a

Jorge Sánchez

MD, MSc, Magíster en Imunología, EAC: Especialista en Alergología Clínica. Grupo de Alergología Clínica y Experimental, IPS universitaria, Universidad de Antioquia.

Claudia Sánchez

Bióloga, Universidad de Antioquia.

Mauricio López

Biólogo, PhD Doctorado en ciencias básicas biomédicas, inmunología. Grupo de Inmunología Celular e Inmunogenética (GICIG), Universidad de Antioquia.

Margarita María Velásquez-Lopera

Dermatóloga, PhD Doctorado en ciencias básicas biomédicas, inmunología. Sección de Dermatología, Centro de Investigaciones Dermatológicas (CIDERM), Universidad de Antioquia.

Citas

1. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4):664-72.
2. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-7.
3. Gaig P, Olona M, Munoz Lejarazu D, Caballero MT, Dominguez FJ, Echechipia S, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3):214-20.
4. Mitchell AE. Bidirectional relationships between psychological health and dermatological conditions in children. Psychol Res Behav Manag. 2018;11:289-98.
5. Arias-Cruz A, González-Díaz SN, Macías-Weinmann A, Ibarra-Chávez JA, Sánchez-Guerra D, Leal-Villarreal L, et al. [Quality of life in chronic urticaria and its relationship with economic impact and disease control in patients attended to at the University Hospital of Monterrey, Mexico]. Rev Alerg Mex. 2018;65(3):170-8.
6. Thomsen SF, Pritzier EC, Anderson CD, Vaugelade-Baust N, Dodge R, Dahlborn AK, et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol. 2017;31(6):1048-55.
7. Sánchez J, Amaya E, Acevedo A, Celis A, Caraballo D, Cardona R. Prevalence of Inducible Urticaria in Patients with Chronic Spontaneous Urticaria: Associated Risk Factors. J Allergy Clin Immunol Pract. 2017;5(2):464-70.
8. Sánchez J, Sánchez A, Cardona R. Dietary Habits in Patients with Chronic Spontaneous Urticaria: Evaluation of Food as Trigger of Symptoms Exacerbation. Dermatol Res Pract. 2018;2018:6703052.
9. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-87.
10. Rivas González AM, Velásquez Franco CJ, Pinto Peñaranda LF, Márquez JD. Urticaria Vasculítica. Revista Colombiana de Reumatología. 2009;16:154-66.
11. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018.
12. Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol. 1999;40(3):443-50.
13. Guttman-Yassky E, Bergman R, Maor C, Mamorsky M, Pollack S, Shahar E. The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals. J Eur Acad Dermatol Venereol. 2007;21(1):35-9.
14. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009;64(9):1256-68.
15. Platzer MH, Grattan CE, Poulsen LK, Skov PS. Validation of basophil histamine release against the autologous serum skin test and outcome of seruminduced basophil histamine release studies in a large population of chronic urticaria patients. Allergy. 2005;60(9):1152-6.
16. Frezzolini A, Provini A, Teofoli P, Pomponi D, De Pita O. Serum-induced basophil CD63 expression by means of a tricolour flow cytometric method for the in vitro diagnosis of chronic urticaria. Allergy. 2006;61(9):1071-7.
17. Wedi B, Novacovic V, Koerner M, Kapp A. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression--inhibitory effects ofanti-inflammatory drugs. J Allergy Clin Immunol. 2000;105(3):552-60.
18. Ye YM, Yang EM, Yoo HS, Shin YS, Kim SH, Park HS. Increased level of basophil CD203c expresión predicts severe chronic urticaria. J Korean Med Sci. 2014;29(1):43-7.
19. Blom T, Nilsson G, Sundstrom C, Nilsson K, Hellman L. Characterization of a human basophillike cell line (LAMA-84). Scandinavian journal of immunology. 1996;44(1):54-61.
20. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol. 1991;88(3 Pt 1):328-38.
21. Ebo DG, Hagendorens MM, Bridts CH, Schuerwegh AJ, De Clerck LS, Stevens WJ. In vitro allergy diagnosis: should we follow the flow? Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2004;34(3):332-9.
22. Vonakis BM, Gibbons S, Jr., Sora R, Langdon JM, MacDonald SM. Src homology 2 domain-containing inositol 5' phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. J Allergy Clin Immunol. 2001;108(5):822-31.
23. Sánchez J, Sánchez A, Cardona R. Causal Relationship Between Anti-TPO IgE and Chronic Urticaria by. Allergy Asthma Immunol Res. 2019;11(1):29-42.
24. Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, et al. Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. Clin Exp Allergy. 2014;44(8):1053-60.
25. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol. 1999;104(1):169-72.
26. Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, Riboldi P, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol. 2007;119(3):705-10.
27. Dos Santos JC, Azor MH, Nojima VY, Lourenco FD, Prearo E, Maruta CW, et al. Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria. International immunopharmacology. 2008;8(10):1433-40.
28. Huilan Z, Runxiang L, Bihua L, Qing G. Role of the subgroups of T, B, natural killer lymphocyte and serum levels of interleukin-15, interleukin-21 and immunoglobulin E in the pathogenesis of urticaria. The Journal of dermatology. 2010;37(5):441-7.
29. Raap U, Wieczorek D, Gehring M, Pauls I, Stander S, Kapp A, et al. Increased levels of serum IL-31 in chronic spontaneous urticaria. Experimental dermatology. 2010;19(5):464-6.
30. Puxeddu I, Italiani P, Giungato P, Pratesi F, Panza F, Bartaloni D, et al. Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. Cytokine. 2013;61(3):741-3.
31. Kessel A, Yaacoby-Bianu K, Vadasz Z, Peri R, Halazs K, Toubi E. Elevated serum B-cell activating factor in patients with chronic urticaria. Human immunology. 2012;73(6):620-2.
32. Futata E, Azor M, Dos Santos J, Maruta C, Sotto M, Guedes F, et al. Impaired IFN-alpha secretion by plasmacytoid dendritic cells induced by TLR9 activation in chronic idiopathic urticaria. Br J Dermatol. 2011;164(6):1271-9.
33. Metz M, Krull C, Hawro T, Saluja R, Groffik A, Stanger C, et al. Substance p is upregulated in the serum of patients with chronic spontaneous urticaria. The Journal of investigative dermatology. 2014;134(11):2833-6.
34. Ozseker F, Buyukozturk S, Gelincik A, Depboylu B, Genc S, Giris M, et al. Neurotrophins: are they meaningful in chronic spontaneous urticaria? Asian Pacific journal of allergy and immunology /launched by the Allergy and Immunology Society of Thailand. 2008;26(2-3):83-8.
35. Elias J, Boss E, Kaplan AP. Studies of the celular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol. 1986;78(5 Pt 1):914-8.
36. Grattan CE, Boon AP, Eady RA, Winkelmann RK. The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. Int Arch Allergy Appl Immunol. 1990;93(2-3):198-204.
37. Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, Barr RM, et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol. 1999;103(3 Pt 1):484-93.
38. Kerstan A, Simon HU, Yousefi S, Leverkus M. Extensive accumulation of eosinophil extracelular traps in bullous delayed-pressure urticaria: a pathophysiological link? Br J Dermatol. 2012;166(5):1151-2.
39. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280-91.
40. Soltani S, Saghazadeh A, Movahedi M, Tavakol M, Sadr M, Farhadi E, et al. FLG single nucleotide polymorphisms in chronic idiopathic urticaria. Allergol Immunopathol (Madr). 2016;44(4):341-5.
41. Ye YM, Kim BE, Shin YS, Park HS, Leung DYM. Increased epidermal filaggrin in chronic idiopathic urticaria is associated with severity of urticaria. Ann Allergy Asthma Immunol. 2014;112(6):533-8.
42. Jagodzinska J, Polaniak R, Birkner E, Kasperska-Zajac A. Analysis of circulating vascular endotelial growth factor and its soluble receptors in patients with different forms of chronic urticaria. Biomed Res Int. 2015;2015:578383.
43. Metz M, Krull C, Maurer M. Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria. J Dermatol Sci. 2013;70(3):222-5.
44. Terhorst D, Koti I, Krause K, Metz M, Maurer M. In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema. Clin Exp Dermatol. 2018;43(2):131-6.
45. Chen T, Guo ZP, Wang WJ, Fu LX, Sun QM, Zhou PM. Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2017;118(6):704-9.
46. Chandrashekar L, Rajappa M, Sundar I, Munisamy M, Ananthanarayanan PH, Thappa DM, et al. Vascular endothelial growth factor levels in patients with chronic urticaria. Clinica chimica acta; international journal of clinical chemistry. 2013;422:44-6.
47. Saini SS. Basophil responsiveness in chronic urticaria. Current allergy and asthma reports. 2009;9(4):286-90.
48. Caproni M, Giomi B, Volpi W, Melani L, Schincaglia E, Macchia D, et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol. 2005;114(3):284-92.
49. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232-47.
50. Pawson T. Regulation and targets of receptor tyrosine kinases. European journal of cancer. 2002;38 Suppl 5:S3-10.
51. Crivellato E, Ribatti D. The mast cell: an evolutionary perspective. Biological reviews of the Cambridge Philosophical Society. 2010;85(2):347-60.
52. Zhang M, Murphy RF, Agrawal DK. Decoding IgE Fc receptors. Immunologic research. 2007;37(1):1-16.
53. Ali H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunology letters. 2010;128(1):36-45.
54. Cardamone C, Parente R, Feo GD, Triggiani M. Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Immunol Lett. 2016;178:10-4.
55. Siracusa MC, Comeau MR, Artis D. New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. Annals of the New York Academy of Sciences. 2011;1217:166-77.
56. Lorenz W, Doenicke A. Histamine release in clinical conditions. The Mount Sinai journal of medicine, New York. 1978;45(3):357-86.
57. Kaliner M, Shelhamer JH, Ottesen EA. Effects of infused histamine: correlation of plasma histamine levels and symptoms. J Allergy Clin Immunol. 1982;69(3):283-9.
58. Flower RJ, Harvey EA, Kingston WP. Inflammatory effects of prostaglandin D2 in rat and human skin. British journal of pharmacology. 1976;56(2):229-33.
59. On M, Billingsley JM, Jouvin MH, Kinet JP. Molecular dissection of the FcRbeta signaling amplifier. The Journal of biological chemistry. 2004;279(44):45782-90.
60. Lin S, Cicala C, Scharenberg AM, Kinet JP. The Fc(epsilon)RIbeta subunit functions as an amplifier of Fc(epsilon)RIgamma-mediated cell activation signals. Cell. 1996;85(7):985-95.
61. Young RM, Holowka D, Baird B. A lipid raft environment enhances Lyn kinase activity by protecting the active site tyrosine from dephosphorylation. The Journal of biological chemistry. 2003;278(23):20746-52.
62. Falcone FH, Knol EF, Gibbs BF. The role of basophils in the pathogenesis of allergic disease. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2011;41(7):939-47.
63. Pribluda VS, Pribluda C, Metzger H. Transphosphorylation as the mechanism by which the highaffinity receptor for IgE is phosphorylated upon aggregation. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(23):11246-50.
64. Yamashita T, Suzuki R, Backlund PS, Yamashita Y, Yergey AL, Rivera J. Differential dephosphorylation of the FcRgamma immunoreceptor tyrosinebased activation motif tyrosines with dissimilar potential for activating Syk. The Journal of biological chemistry. 2008;283(42):28584-94.
65. Kimura T, Hisano M, Inoue Y, Adachi M. Tyrosine phosphorylation of the linker for activator of T cells in mast cells by stimulation with the high affinity IgE receptor. Immunology letters. 2001;75(2):123-9.
66. Gonzalez-Espinosa C, Odom S, Olivera A, Hobson JP, Martinez ME, Oliveira-Dos-Santos A, et al. Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. The Journal of experimental medicine. 2003;197(11):1453-65.
67. Siraganian RP, de Castro RO, Barbu EA, Zhang J. Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS letters. 2010;584(24):4933-40.
68. Bugajev V, Bambouskova M, Draberova L, Draber P. What precedes the initial tyrosine phosphorylation of the high affinity IgE receptor in antigen-activated mast cell? FEBS letters. 2010;584(24):4949-55.
69. Rauber MM, Pickert J, Holiangu L, Möbs C, Pfützner W. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria. Allergy. 2017.
70. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129(5):1307-13.
71. Kim YS, Han K, Lee JH, Kim NI, Roh JY, Seo SJ, et al. Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study. Allergy Asthma Immunol Res. 2017;9(4):373-7.
72. Sánchez Jorge J, Sánchez A, Cardona R. Prevalence of drugs as triggers of exacerbations in chronic urticaria. J Investig Allergol Clin Immunol. 2018:0.
73. Sánchez J, Zakzuk J, Cardona R. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria. J Allergy Clin Immunol Pract. 2018;6(1):177-82.e1.
74. Sánchez JM, Ramírez RH, Tamayo LM, Chinchilla CF, Cardona R. [Cold urticaria: case series and literatura review]. Biomedica. 2011;31(2):168-77.
75. Maurer M, Altrichter S, Schmetzer O, Scheffel J, Church MK, Metz M. Immunoglobulin E-Mediated Autoimmunity. Front Immunol. 2018;9:689.
76. Grattan C. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;141(3):1165-6.
77. Sánchez-Borges M, Acevedo N, Caraballo L, Capriles-Hulett A, Caballero-Fonseca F. Increased total and mite-specific immunoglobulin E in patients with aspirin-induced urticaria and angioedema. J Investig Allergol Clin Immunol. 2010;20(2):139-45.
78. Sánchez J, Zakzuk J, Cardona R. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine- Induced Wheal. J Investig Allergol Clin Immunol. 2016;26(3):177-84.
79. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017;72(10):1440-60.
80. Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794.
81. Shin YS, Suh DH, Yang EM, Ye YM, Park HS. Serum Specific IgE to Thyroid Peroxidase Activates Basophils in Aspirin Intolerant Urticaria. J Korean Med Sci. 2015;30(6):705-9.
82. Nuzzo V, Tauchmanova L, Colasanti P, Zuccoli A, Colao A. Idiopathic chronic urticaria and thyroid autoimmunity: Experience of a single center. Dermato-endocrinology. 2011;3(4):255-8.
83. Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2017.
84. Concha LB, Chang CC, Szema AM, Dattwyler RJ, Carlson HE. IgE antithyroid antibodies in patients with Hashimoto's disease and chronic urticaria. Allergy and asthma proceedings : the official journal of regional and state allergy societies. 2004;25(5):293-6.
85. Hatada Y, Kashiwakura J, Hayama K, Fujisawa D, Sasaki-Sakamoto T, Terui T, et al. Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients. International archives of allergy and immunology. 2013;161 Suppl 2:154-8.
86. Grattan CE, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy. 1991;21(6):695-704.
87. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599-604.
88. Grattan CE. Histamine-releasing autoantibodies in chronic urticaria. Skin Pharmacol. 1991;4 Suppl 1:64-70.
89. Ulambayar B, Chen YH, Ban GY, Lee JH, Jung CG, Yang EM, et al. Detection of circulating IgG autoantibody to FcεRIα in sera from chronic spontaneous urticaria patients. J Microbiol Immunol Infect. 2017.
90. Lee MF, Lin TM, Liu SW, Chen YH. A rapid method of detecting autoantibody against FcεRIα for chronic spontaneous urticaria. PLoS One. 2014;9(10):e109565.
91. Yoshimasu T, Furukawa F. Eradication therapy for urticaria with high titers of anti H. pylori IgG antibody. Allergol Int. 2014;63(1):37-40.
92. Burak Selek M, Baylan O, Kutlu A, Özyurt M. Toxocara Canis IgG Seropositivity in Patients with Chronic Urticaria. Iran J Allergy Asthma Immunol. 2015;14(4):450-6.
93. Brzoza Z, Grzeszczak W, Trautsolt W, Moczulski D. Inducible T-cell costimulator (ICOS) and CD28 polymorphisms possibly play a role in the pathogenesis of chronic autoreactive urticaria. Clin Exp Dermatol. 2017;42(8):863-7.
94. Palikhe NS, Kim SH, Ye YM, Hur GY, Cho BY, Park HS. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics. 2009;10(3):375-83.
95. Auyeung P, Mittag D, Hodgkin PD, Harrison LC. Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iα subunit. J Allergy Clin Immunol. 2016;138(3):761-8.e4.
96. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergeninduced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109(4):694-700.
97. Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. The Journal of clinical investigation. 1998;101(1):243-51.
98. Tedeschi A, Lorini M, Suli C, Asero R. No evidence of tumor necrosis factor-alpha release in blood of patients with chronic urticaria. Allergy. 2006;61(4):510-1.
99. Piconi S, Trabattoni D, Iemoli E, Fusi ML, Villa ML, Milazzo F, et al. Immune profiles of patients with chronic idiopathic urticaria. International archives of allergy and immunology. 2002;128(1):59-66.
100. Merluzzi S, Betto E, Ceccaroni AA, Magris R, Giunta M, Mion F. Mast cells, basophils and B cell connection network. Molecular immunology. 2015;63(1):94-103.
101. Wang SF, Gao XQ, Xu YN, Li DN, Wang HY, He SH. Elevated Plasma Level of Interferon-λ1 in Chronic Spontaneous Urticaria: Upregulated Expression in CD8(+) and Epithelial Cells and Induction of Inflammatory Cell Accumulation. Mediators Inflamm. 2016;2016:5032051.
102. Chen Q, Zhong H, Chen WC, Zhai Z, Zhou Z, Song Z, et al. Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2018;32(3):441-8.
103. Degirmenci PB, Kırmaz C, Vatansever S, Onur E, Nal E, Erdin S, et al. Analysis of the association of chronic spontaneous urticaria with interlekin-4, -10, transforming growth factor-β1, interferon-γ, interleukin-17A and -23 by autologous serum skin test. Postepy Dermatol Alergol. 2017;34(1):70-6.
104. Moy AP, Murali M, Nazarian RM. Identification of a Th2- and Th17-skewed immune phenotype in chronic urticaria with Th22 reduction dependent on autoimmunity and thyroid disease markers. J Cutan Pathol. 2016;43(4):372-8.
105. Arshi S, Babaie D, Nabavi M, Tebianian M, Ghalehbaghi B, Jalali F, et al. Circulating level of CD4+ CD25+ FOXP3+ T cells in patients with chronic urticaria. Int J Dermatol. 2014;53(12):e561-6.
106. Zheng R, Qian L, Yu J, Li M, Qian Q. Analysis of the changes in Th9 cells and related cytokines in the peripheral blood of spontaneous urticaria patients. Biomed Rep. 2017;6(6):633-9.
107. Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol. 2002;109(1):114-8.
108. Kasperska-Zajac A. Acute-phase response in chronic urticaria. J Eur Acad Dermatol Venereol. 2012;26(6):665-72.
109. Kasperska-Zajac A, Grzanka A, Machura E, Mazur B, Misiolek M, Czecior E, et al. Analysis of procalcitonin and CRP concentrations in serum of patients with chronic spontaneous urticaria. Inflammation research : official journal of the European Histamine Research Society [et al]. 2013;62(3):309-12.
110. Kasperska-Zajac A, Sztylc J, Machura E, Jop G. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2011;41(10):1386-91.
111. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort. Journal of clinical laboratory analysis. 2004;18(1):1-8.
112. Kasperska-Zajac A, Grzanka A, Machura E, Misiolek M, Mazur B, Jochem J. Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration. Journal of inflammation. 2013;10(1):22.
113. Zweiman B, Valenzano M, Atkins PC, Tanus T, Getsy JA. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol. 1996;98(1):89-98.
114. Sugita Y, Morita E, Kawamoto H, Horiuchi K, Yamada S, Koro O, et al. Correlation between deposition of immuno-components and infiltration pattern of polymorphonuclear leukocytes in the lesions of chronic urticaria. J Dermatol. 2000;27(3):157-62.
115. Metz M, Gimenez-Arnau A, Borzova E, Grattan CE, Magerl M, Maurer M. Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. J Allergy Clin Immunol. 2009;123(3):705-6.
116. Grzanka R, Damasiewicz-Bodzek A, Kasperska-Zajac A. Interplay between acute phase response and coagulation/fibrinolysis in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2018;14:27.
117. Asero R, Marzano AV, Ferrucci S, Cugno M. DDimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria. Int Arch Allergy Immunol. 2017;172(1):40-4.
118. Kolkhir P, André F, Church MK, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017;47(1):19-36.
119. Kolkhir P, Pogorelov D, Olisova O. CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2017;49(4):189-92.
120. Tversky JR, Le TV, Bieneman AP, Chichester KL, Hamilton RG, Schroeder JT. Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2008;38(5):781-8.
121. Mazzoni A, Leifer CA, Mullen GE, Kennedy MN, Klinman DM, Segal DM. Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells. Journal of immunology. 2003;170(5):2269-73.
122. Santos JC, de Brito CA, Futata EA, Azor MH, Orii NM, Maruta CW, et al. Up-regulation of chemokine C-C ligand 2 (CCL2) and C-X-C chemokine 8 (CXCL8) expression by monocytes in chronic idiopathic urticaria. Clin Exp Immunol. 2012;167(1):129-36.
123. Dimitrijevic M, Stanojevic S, Kustrimovic N, Leposavic G. End-point effector stress mediators in neuroimmune interactions: their role in immune system homeostasis and autoimmune pathology. Immunologic research. 2012;52(1-2):64-80.
124. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006;61(3):316-20.
125. Tedeschi A, Lorini M, Asero R. No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors. Clinical and experimental dermatology. 2005;30(2):171-5.
126. Namura K, Hasegawa G, Egawa M, Matsumoto T, Kobayashi R, Yano T, et al. Relationship of serum brain-derived neurotrophic factor level with other markers of disease severity in patients with atopic dermatitis. Clin Immunol. 2007;122(2):181-6.
127. Noga O, Englmann C, Hanf G, Grutzkau A, Seybold J, Kunkel G. The production, storage and reléase of the neurotrophins nerve growth factor, brainderived neurotrophic factor and neurotrophin-3 by human peripheral eosinophils in allergics and non-allergics. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2003;33(5):649-54.
128. Rossing K, Novak N, Mommert S, Pfab F, Gehring M, Wedi B, et al. Brain-derived neurotrophic factor is increased in serum and skin levels of patients with chronic spontaneous urticaria. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2011;41(10):1392-9.
129. Belsito DV. Second-generation antihistamines for the treatment of chronic idiopathic urticaria. Journal of drugs in dermatology : JDD. 2010;9(5):503-12.
130. Grant JA, Bernstein DI, Buckley CE, Chu T, Fox RW, Rocklin RE, et al. Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1988;81(3):574-9.
131. Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386-90.
132. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122(3):569-73.
133. Grattan CE, O'Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized doubleblind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol. 2000;143(2):365-72.
134. Zimmerman AB, Berger EM, Elmariah SB, Soter NA. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol. 2012;66(5):767-70.
135. Boers M. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis and rheumatism. 2011;63(2):329-30.
136. Villoutreix BO, Laconde G, Lagorce D, Martineau P, Miteva MA, Dariavach P. Tyrosine kinase syk nonenzymatic inhibitors and potential anti-allergic.
Cómo citar
1.
Sánchez J, Sánchez C, López M, Velásquez-Lopera MM. Mecanismos inmunitarios en la patogénesis de la urticaria crónica espontánea. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 15 de abril de 2021 [citado 10 de mayo de 2021];29(1):14-8. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1588

Descargas

La descarga de datos todavía no está disponible.
Publicado
2021-04-15
Sección
Artículo de revisión

Artículos más leídos del mismo autor/a